The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

Launched by UNIVERSITY HOSPITAL TUEBINGEN · Sep 23, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CC-1 for men with castration-resistant prostate cancer, which means their cancer continues to grow despite hormone therapy. The trial is in its first phase and aims to find out how safe and effective CC-1 is for patients who have already tried other treatments. CC-1 is a special type of antibody that targets cancer cells and helps the immune system fight the cancer while minimizing side effects. Participants will receive CC-1 along with a medication called tocilizumab to help manage any potential side effects.

To be eligible for this trial, participants must be adult men who have been diagnosed with castration-resistant prostate cancer and have already undergone at least three previous treatments. They should have a life expectancy of more than three months and be able to follow the study guidelines. Participants can expect to have regular check-ups, including scans to monitor their cancer, and will be closely watched for any reactions to the treatment. This trial is currently recruiting and aims to gather valuable information that could improve future cancer treatments.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• Patients with CRPC will be included in this clinical trial. Patients must meet all of the following inclusion criteria to be eligible for enrolment into the study:
• • Existence of a written informed consent
• • Patient is able to understand and comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
• • CRPC after third line therapy
• • Life expectance of \> 3 months
• • At least one measurable lesion that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment
• • Eastern Cooperative Oncology Group Performance (ECOG) Status ≤ 2
• • Patient aged ≥ 18, no upper age limit
• • Male patients with partners of child-bearing potential, who are sexually active, must agree to the use of two highly effective forms of contraception. This should be started from the signing of the informed consent and continue throughout period of taking study treatment for 3 months after last dose of study drug.
• * Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:
• • Hemoglobin ≥ 10 g/dl
• • Neutrophil count ≥ 1,500/mm3
• • Platelet count ≥ 100,000/μl
• • Bilirubin ≤ 1.5 x upper limit of normal (ULN)
• • ALT and AST ≤ 2.5 x ULN
• • Alkaline phosphatase ≤ 2.5 x ULN
• • PT-INR/PTT ≤ 1.5 x ULN
• • Creatine kinase ≤ 2.5 x ULN
• • Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min
• Exclusion Criteria:
• Patients fulfilling any of the following criteria cannot be enrolled in the trial:
• • Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer
• • Concurrent or previous treatment within 30 days in another interventional clinical trial with an investigational anticancer therapy
• • Persistent toxicity (≥Grade 2 according to Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) caused by previous cancer therapy, excluding alopecia and neurotoxicity (≤ 2 grade)
• • Clinical signs of active infection (\>Grade 2 according to CTCAE version 5.0)
• • History of HIV infection
• • Immunocompromised patients
• • Active or chronic viral hepatitis (HBV or HCV)
• • History of autoimmune disease
• • History of relevant CNS pathology or current relevant CNS pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder) Epilepsy requiring pharmacologic treatment
• • Therapeutic anticoagulation therapy
• • Major surgery within 4 weeks of starting study treatment. Patients must have recovered from any effects of major surgery.
• • Patients receiving any systemic chemotherapy or radiotherapy within 2 weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used
• • Heart failure NYHA III/IV
• • Severe obstructive or restrictive ventilation disorder
• • Known history of GI-perforation
• • Pre-existing HAHA
• • Known intolerance to CC-1, tocilizumab or other immunoglobulin drug products as well as hypersensitivity to any of the excipients present in the respective drug products (CC-1, tocilizumab)